<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651715</url>
  </required_header>
  <id_info>
    <org_study_id>ESTUAR001</org_study_id>
    <nct_id>NCT01651715</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections</brief_title>
  <acronym>ESTUAR</acronym>
  <official_title>Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Study Evaluating the Efficacy and Safety of Early Self-Treatment of Viral Upper Respiratory Tract Infections With Homeopathic Oral Antibodies to the TLR3 FYW Peptide (TAO1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranor s.p.r.l</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranor s.p.r.l</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether early self-treatment with homeopathic&#xD;
      dilutions of oral antibodies to a key-protein of the immune system are effective and safe in&#xD;
      the treatment of viral upper respiratory tract infections&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TAO1 is an investigational medicinal product containing homoeopathic dilutions (&lt;10-24M) of&#xD;
      antibodies purified from the serum of rabbit immunised against a synthetic peptide with an&#xD;
      amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It&#xD;
      is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as&#xD;
      common cold, influenza or influenza-like illnesses.&#xD;
&#xD;
      The validity of the TAO1 development approach was addressed in a proof of concept study of&#xD;
      efficacy in a non-lethal influenza infection in mice. In this blinded study, TAO1 was given&#xD;
      in drinking water for 5 days before and 10 days after viral challenge. The statistical&#xD;
      analysis of preclinical data was carried out by using the Mann-Whitney non-parametric test&#xD;
      (2-tailed). The clinical disease duration was significantly reduced from 6.0 (5.25 (25th&#xD;
      percentile);7.0 (75th percentile)) days to 5.0 (5.0;5.0) days (p=0.00037) as well as the&#xD;
      overall disease severity that was lowered from 8.0 (7.0;10.0) points to 6.0 (5.0;7.5) points&#xD;
      (p=0.00032).&#xD;
&#xD;
      Given the high homoeopathic dilution, the active substance in the finished product lies&#xD;
      beyond sensitivity of existing analytical assays. TAO1 is therefore not amenable to&#xD;
      pharmacokinetics studies.&#xD;
&#xD;
      There are currently no data on clinical efficacy of TAO1 in common cold obtained in&#xD;
      double-blind placebo-controlled clinical trials. Based on the efficacy in the animal model,&#xD;
      the expected magnitude of effect of TAO1 in humans is a reduction of common cold duration by&#xD;
      2-3 days, provided that the treatment is started early after the onset of the symptoms.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To evaluate the efficacy of TAO1 in reducing the severity of symptoms of common cold in&#xD;
      otherwise healthy adults.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      To evaluate the efficacy of TAO1 in reducing the duration of common cold. To evaluate the&#xD;
      impact of TAO1 on health-related Quality of Life (functional impairment) in patients with&#xD;
      common cold.&#xD;
&#xD;
      To evaluate the safety of TAO1.&#xD;
&#xD;
      Experimental design: Double-blind, parallel-group, randomised, multicentre,&#xD;
      placebo-controlled study.&#xD;
&#xD;
      Treatment allocation: Balanced allocation between TAO1 and placebo (1:1).&#xD;
&#xD;
      At Visit 1, the medications, questionnaires and diary cards will be dispensed to patients who&#xD;
      have signed informed consent. Upon contracting a common cold, they will start the treatment&#xD;
      immediately and take contact with the doctor by phone within 36 hours. On Day 2-3 after the&#xD;
      onset of disease, they will visit the doctor (Visit 2) to confirm the diagnosis. The doctor&#xD;
      will check if questionnaires are filled in correctly. On the 10-14th day (at the latest)&#xD;
      after start of treatment, Visit 3 is planned to pick up questionnaires, evaluate safety,&#xD;
      disease complications and treatment compliance.&#xD;
&#xD;
      Treatment group: TAO1 tablets (to be dissolved in the mouth, not to be swallowed; should be&#xD;
      taken at least 10 minutes apart from meals and/or smoking):&#xD;
&#xD;
      Day 1: 3 tablets to be taken over the first 2 hours of treatment, then 3 tablets over the&#xD;
      rest of Day 1,&#xD;
&#xD;
      Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime),&#xD;
&#xD;
      Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).&#xD;
&#xD;
      Control: Placebo tablets: same dosage regimen as for TAO1.&#xD;
&#xD;
      Concomitant medications: Only oral analgesics/antipyretics, such as paracetamol or ibuprofen,&#xD;
      will be allowed in case of fever or headache. Each intake of such medications will be&#xD;
      registered in the patient's diary.&#xD;
&#xD;
      Severity and duration of self-reported symptoms evaluated daily by the validated Wisconsin&#xD;
      Upper Respiratory Symptom Survey short version (WURSS-21)&#xD;
&#xD;
      Evaluation of safety: adverse events (AEs) and serious adverse events (SAEs) coded using the&#xD;
      Medical Dictionary for Regulatory Activities (MedDRA) assessed according to their frequency,&#xD;
      severity, outcome and relationship to the study drug.&#xD;
&#xD;
      Data collection: Paper Case Report Form (CRF).&#xD;
&#xD;
      Duration of treatment: 7 days&#xD;
&#xD;
      Duration of study: maximum 10 months.&#xD;
&#xD;
      Number of Investigators: about 35 investigators (General Practitioners).&#xD;
&#xD;
      Type of study: Phase II, self-contained study&#xD;
&#xD;
      Number of patients: 240 (120 treated with TAO1 and 120 treated with placebo)&#xD;
&#xD;
      Sample size justification: A sample size of 115 in each group will have 80% power to detect a&#xD;
      difference in mean AUCs of 103 (a difference of 30% between a Placebo AUC mean of 310 and a&#xD;
      TAO1 AUC mean of 207) assuming that the common standard deviation is 277 using a two group&#xD;
      t-test with a 0.050 two-sided significance level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of symptoms of common cold</measure>
    <time_frame>Since start of symptoms of common cold up to the visit 3 (day 10-14)</time_frame>
    <description>Decrease in severity is assessed as reduction in average area under the curve (AUC) under the time severity curve (sum of all WURSS scores over the follow-up). The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) is a validated tool to evaluate the duration and severity of common cold. It is constituted of twenty-one categorical questions (Likert-type 7-level severity scale).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of common cold</measure>
    <time_frame>Since start of symptoms of common cold up to visit 3 (Day 10-14)</time_frame>
    <description>Duration is defined as the number of days from self-reported onset of disease to the last day before the participant answered &quot;Not sick&quot; to the question, &quot;How sick do you feel today?&quot; (WURSS-21). A 2-day reduction in average disease duration versus placebo will be regarded as clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional impairments in the course of the disease</measure>
    <time_frame>Since start of symptoms of common cold up to visit 3 (Day 10-14)</time_frame>
    <description>Day-to-day scores for functional impairments domain. Overall (sum of all WURSS scores related to functional impairments over the follow-up).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need of symptomatic analgesics/antipyretics</measure>
    <time_frame>Since start of symptoms of common cold up to visit 3 (Day 10-14)</time_frame>
    <description>Patients will fill in diary cards on a daily basis. The following information will be recorded: study and patient identification, date of assessment, study medication intake, other medications (name, dose, frequency) and, AEs/SAEs (description)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety</measure>
    <time_frame>since start of symptoms of common cold up to visit 3 (Day 10-14)</time_frame>
    <description>Patients will fill in diary cards on a daily basis including AEs/SAEs reporting. Investigators will question patients at phone call and scheduled visits about AEs/SAEs. Frequency, severity, outcome and relationship to the study drug will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>TAO1, oral homeopathic antibodies</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAO1 is an investigational medicinal product containing homeopathic dilutions (&lt;10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAO1, oral homeopathic antibodies</intervention_name>
    <description>TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).&#xD;
The investigational product will be taken for 7 days as follow:&#xD;
Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.&#xD;
Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAO1, oral homeopathic antibodies</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients aged &gt; or = 18 years&#xD;
&#xD;
          -  Ability and willingness to adhere to the study protocol&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Self-reported recently emerged symptoms of common cold: answer &quot;Yes&quot; to the question&#xD;
             &quot;Do you believe that you are coming down with a cold?&quot;&#xD;
&#xD;
          -  At least one of the following 4 common cold symptoms: sneezing, runny nose, nasal&#xD;
             obstruction and/or sore throat, with no limitations of symptom severity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specific chronic diseases (autoimmune disease, chronic bronchitis, human&#xD;
             immunodeficiency virus (HIV) infection, lupus, rheumatoid arthritis)&#xD;
&#xD;
          -  Malignancy for which the patient has undergone resection, radiation or chemotherapy&#xD;
             within the last five years. Patients with treated basal cell carcinoma are allowed.&#xD;
&#xD;
          -  Cancer therapy&#xD;
&#xD;
          -  Immunosuppressant therapies&#xD;
&#xD;
          -  Use of systemic corticosteroids&#xD;
&#xD;
          -  A history of asthma or allergic rhinitis and corresponding symptoms (itchy eyes,&#xD;
             sneezing, wheezing)&#xD;
&#xD;
          -  Any of the common cold symptoms persisting since more than 36 hours&#xD;
&#xD;
          -  Use of other homeopathic drugs designed to treat URTIs&#xD;
&#xD;
          -  Use of antibiotics, anti-histaminergic drugs or decongestants&#xD;
&#xD;
          -  Participation in another clinical trial within one month prior to treatment start&#xD;
&#xD;
          -  Previous participation (receipt of randomised treatment) in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Heijmans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RESEARCHLINK sprl</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc Moriau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ECSOR sa/nv</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Thiry, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>THERANOR sprl</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frank Heyvaert</name>
      <address>
        <city>Deurne</city>
        <state>Antwerpen</state>
        <zip>2100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christel Van Der Geer</name>
      <address>
        <city>Geel</city>
        <state>Antwerpen</state>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hugo Loos</name>
      <address>
        <city>Geel</city>
        <state>Antwerpen</state>
        <zip>2440</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Joris</name>
      <address>
        <city>Mol</city>
        <state>Antwerpen</state>
        <zip>2400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan De Jongh</name>
      <address>
        <city>Vorst</city>
        <state>Antwerpen</state>
        <zip>2430</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Pierre Devaux</name>
      <address>
        <city>Baisy-Thy</city>
        <state>Brabant</state>
        <zip>1470</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginie Risse</name>
      <address>
        <city>Bruxelles</city>
        <state>Brabant</state>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roel De Ryck</name>
      <address>
        <city>Kraainem</city>
        <state>Brabant</state>
        <zip>1950</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ResearchLink sprl</name>
      <address>
        <city>Linkebeek</city>
        <state>Brabant</state>
        <zip>1630</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stéphane Vanden Bemden</name>
      <address>
        <city>Melsbroek</city>
        <state>Brabant</state>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bart Van Essche</name>
      <address>
        <city>Steenokkerzeel</city>
        <state>Brabant</state>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erik Schreurs</name>
      <address>
        <city>Tremelo</city>
        <state>Brabant</state>
        <zip>3120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lode Vermeersch</name>
      <address>
        <city>Tremelo</city>
        <state>Brabant</state>
        <zip>3120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luc De Munck</name>
      <address>
        <city>Vilvoorde</city>
        <state>Brabant</state>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patrice Lechien</name>
      <address>
        <city>Braine-le-Comte</city>
        <state>Hainaut</state>
        <zip>7090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Corbisier</name>
      <address>
        <city>Ecaussinnes</city>
        <state>Hainaut</state>
        <zip>7190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elise De Meulemeester</name>
      <address>
        <city>Gozée</city>
        <state>Hainaut</state>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magali Trefois</name>
      <address>
        <city>Gozée</city>
        <state>Hainaut</state>
        <zip>6534</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aubry Robert</name>
      <address>
        <city>Ham-sur-Heure Nalinnes</city>
        <state>Hainaut</state>
        <zip>6120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippe Jacques</name>
      <address>
        <city>Ham-sur-Heure Nalinnes</city>
        <state>Hainaut</state>
        <zip>6120</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michel Grégoire</name>
      <address>
        <city>Pont-à-Celles</city>
        <state>Hainaut</state>
        <zip>6230</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etienne Demanet</name>
      <address>
        <city>Thuin</city>
        <state>Hainaut</state>
        <zip>6530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Buscemi</name>
      <address>
        <city>Thuin</city>
        <state>Hainaut</state>
        <zip>6530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etienne Plees</name>
      <address>
        <city>Beringen</city>
        <state>Limburg</state>
        <zip>3580</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicole Olaerts</name>
      <address>
        <city>Ham</city>
        <state>Limburg</state>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Beke</name>
      <address>
        <city>Leopoldsburg</city>
        <state>Limburg</state>
        <zip>3970</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Windmolders</name>
      <address>
        <city>Overpelt</city>
        <state>Limburg</state>
        <zip>3900</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Behets</name>
      <address>
        <city>Paal</city>
        <state>Limburg</state>
        <zip>3583</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jos Weckx</name>
      <address>
        <city>Paal</city>
        <state>Limburg</state>
        <zip>3583</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herman Van Den Broeck</name>
      <address>
        <city>Tessenderlo</city>
        <state>Limburg</state>
        <zip>3980</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yvan Calozet</name>
      <address>
        <city>Gribomont</city>
        <state>Luxembourg</state>
        <zip>6887</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierre-Henri Arnould</name>
      <address>
        <city>Libramont-Chevigny</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy Van Damme</name>
      <address>
        <city>Heusden</city>
        <state>Oost Vlaanderen</state>
        <zip>9070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

